TARO-DOCETAXEL SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

DOCETAXEL

から入手可能:

TARO PHARMACEUTICALS INC

ATCコード:

L01CD02

INN（国際名）:

DOCETAXEL

投薬量:

20MG

医薬品形態:

SOLUTION

構図:

DOCETAXEL 20MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

5ML

処方タイプ:

Prescription

治療領域:

ANTINEOPLASTIC AGENTS

製品概要:

Active ingredient group (AIG) number: 0127884004; AHFS:

認証ステータス:

CANCELLED PRE MARKET

承認日:

2022-07-11

製品の特徴

_ _
_Pr_
_Taro-Docetaxel - Product Monograph _
_ _
_Page 1 of 57 _
PRODUCT MONOGRAPH
PR
TARO-DOCETAXEL
(Docetaxel for Injection)
Single Vial Formulation
CONCENTRATED SOLUTION
20 MG / ML
80 MG / 4 ML
160 MG / 8 ML
USP Standard
FOR INTRAVENOUS INFUSION, MUST BE DILUTED BEFORE USE
ANTINEOPLASTIC AGENT
Taro Pharmaceuticals Inc.
Date of Revision:
130 East Drive, Brampton August 10, 2021
Ontario L6T 1C1
Submission Control No: 253784
_ _
_Pr_
_Taro-Docetaxel - Product Monograph _
_ _
_Page 2 of 57 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
..................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................27
DOSAGE AND ADMINISTRATION
..............................................................................28
OVERDOSAGE
................................................................................................................31
ACTION AND CLINICAL PHARMACOLOGY
............................................................32
STORAGE AND STABILITY
..........................................................................................33
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................34
PART II: SCIENTIFIC INFORMATION
....................................................................35
PHARMACEUTICAL INFORMATION
..........................................................................35
CLINICAL TRIALS
.............................................................